Literature DB >> 24170765

Antihypertensive treatment and resistant hypertension in patients with type 1 diabetes by stages of diabetic nephropathy.

Raija Lithovius1, Valma Harjutsalo, Carol Forsblom, Markku Saraheimo, Per-Henrik Groop.   

Abstract

OBJECTIVE: To assess blood pressure (BP) control, antihypertensive treatment, and prevalence of resistant hypertension (RH) in patients with type 1 diabetes stratified by stage of diabetic nephropathy. RESEARCH DESIGN AND METHODS: This cross-sectional study included a nationally representative cohort of patients with type 1 diabetes (N = 3,678) from the Finnish Diabetic Nephropathy Study (FinnDiane). The data were linked to the Drug Prescription Register to obtain purchases of antihypertensive drugs 6 months prior to the baseline visit. The treatment targets were based on the American Diabetes Association guidelines. RH was defined as failure to reach BP target despite the use of three or more antihypertensive drugs of different classes (one of which was a diuretic).
RESULTS: In patients with normal albumin excretion rate, 14.1% were on antihypertensive treatment and 74.6% of them had uncontrolled BP despite treatment. The corresponding figures were 60.5 and 71.2% for the microalbuminuric patients, 90.3 and 80.0% for the macroalbuminuric patients, 88.6 and 88.1% for dialysis, and 91.2 and 90.4% for kidney-transplanted patients. The prevalence of RH was 1.2% in the normoalbuminuric, 4.7% in the microalbuminuric, 28.1% in the macroalbuminuric, 36.6% in the dialysis, and 26.3% in the kidney transplant groups. Age (odds ratio 1.04 [95% CI 1.02-1.05]), estimated glomerular filtration rate (0.97 [0.96-0.97]), waist-to-hip ratio (1.44 [1.15-1.80]), triglycerides (1.19 [1.01-1.40]), microalbuminuria (2.58 [1.43-4.67]), and macroalbuminuria (5.61 [3.20-9.84]) were independently associated with RH.
CONCLUSIONS: The prevalence of uncontrolled hypertension and RH increases with advanced diabetic nephropathy. These data suggest that there is an urgent need for improvement of antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24170765     DOI: 10.2337/dc13-2023

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Ambulatory blood pressure and arterial stiffness in individuals with type 1 diabetes.

Authors:  Raija Lithovius; Daniel Gordin; Carol Forsblom; Markku Saraheimo; Valma Harjutsalo; Per-Henrik Groop
Journal:  Diabetologia       Date:  2018-05-24       Impact factor: 10.122

Review 2.  Resistant hypertension in diabetes mellitus.

Authors:  George Bayliss; Larry A Weinrauch; John A D'Elia
Journal:  Curr Diab Rep       Date:  2014-08       Impact factor: 4.810

3.  Prevalence and characteristics of resistant hypertension at primary clinics in Korea: a nationwide cross-sectional study.

Authors:  Kwang No Lee; Jin Oh Na; Cheol Ung Choi; Hong Euy Lim; Jin Won Kim; Eung Ju Kim; Seung-Woon Rha; Hong Seog Seo; Dong Joo Oh; Chang Gyu Park
Journal:  Clin Hypertens       Date:  2016-01-31

4.  Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.

Authors:  D Banerjee; P Winocour; T A Chowdhury; P De; M Wahba; R Montero; D Fogarty; A H Frankel; J Karalliedde; P B Mark; D C Patel; A Pokrajac; A Sharif; S Zac-Varghese; S Bain; I Dasgupta
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388

5.  Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients.

Authors:  Larry A Weinrauch; George Bayliss; Alissa R Segal; Jiankang Liu; Eric Wisniewski; John A D'Elia
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-03-02       Impact factor: 3.738

Review 6.  Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease.

Authors:  Guanghong Jia; James R Sowers
Journal:  Hypertension       Date:  2021-10-04       Impact factor: 10.190

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.